search
Back to results

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Primary Purpose

Non Small Cell Lung Cancer

Status
Terminated
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
AC0010MA
Sponsored by
ACEA Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Is male or female, aged 18 years or older at the time of consent; preferably non-Asian.
  2. Has histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC.
  3. Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  4. Has documented evidence of an activating EGFR mutation in the tumor tissue determined by either sequencing or PCR-based technique (Part 1).
  5. For Part 1 only: subjects with a positive T790M mutation are preferred, but not required. Confirmation of T790M mutation status will be determined from an archived tumor tissue sample or fresh tumor tissue sample obtained via biopsy if archived tissue is not available. In Part 2, subjects must have a confirmed, positive T790M EGFR mutation (acquired T790M EGFR mutation or "de novo" T790M EGFR mutation).
  6. Has a life expectancy of at least 3 months.
  7. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. Has adequate hematological and physiological functions.
  9. Has documented disease progression while receiving at least 30 days of treatment with a currently approved EGFR tyrosine kinase inhibitor (TKI) (e.g., erlotinib, gefitinib or afatinib) with intervening treatment after most recent EGFR TKI therapy (not required for "de novo" T790M EGFR mutation).
  10. Signed and dated written informed consent obtained prior to any study-specific evaluation.

Exclusion Criteria:

  1. Has a history of interstitial lung disease related to prior EGFR inhibitor therapy.
  2. Has an EGFR TKI- related toxicity that has NOT resolved to Grade 1 or less.
  3. Is test positive for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) antibody.
  4. Has received the prohibited therapy (e.g., concurrent anti-cancer therapy including but not limited to: chemotherapy, radiation, hormonal, or immunotherapy) ≤14 days prior to first planned dose of AC0010MA.
  5. Received prior treatment with AZD9291 (osimertinib) or CO1686 (rociletinib) and experienced disease progression.
  6. Is a female subject who is pregnant or breastfeeding.
  7. Female subjects (if of child bearing potential) and male subjects (with a partner of child bearing potential) must use medically acceptable methods of birth control before study entry, for the duration of the study, and for at least 6 months after the last intake of study drug.
  8. Has a serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled psychiatric condition, uncontrolled intercurrent illness including active infection, arterial thrombosis, or symptomatic pulmonary embolism).
  9. Has any other reason(s) for the investigator to consider that the subject should not participate in the study.
  10. Is receiving treatment with medication(s) that are known to be strong inhibitors or inducers of CYP3A4/5.

Sites / Locations

  • City of Hope Comprehensive Cancer Center
  • Stanford University
  • Emory University School of Medicine
  • MD Anderson Cancer Center
  • CEPCM - Hopital Timone
  • Hospital Universitari Vall d'Hebron
  • START-Madrid-FJD
  • START-Madrid-CIOCC

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

single dose per day (QD)

two doses per day (BID)

Arm Description

Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.

Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).

Outcomes

Primary Outcome Measures

Safety and tolerability, and the maximum tolerated dose (MTD) of AC0010MA determined by incidence of dose limiting toxicity (DLT)
To determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of AC0010MA by incidence of dose limiting toxicity (DLT), defined as Grade 3 or 4 adverse events (AEs) and clinical lab abnormalities occurring within the first 28 days of treatment.

Secondary Outcome Measures

Evaluation of tumor response and duration of response of AC0010MA ((objective response rate, ORR)
To characterize tumor response (objective response rate, ORR) and duration of response of AC0010MA as a criterion for further development of AC0010MA in this patient population.
Maximum plasma concentration (Cmax) of AC0010MA
To evaluate pharmacokinetic parameter of AC0010MA
Time to Cmax
To evaluate pharmacokinetic parameter of AC0010MA
Terminal half-life (t1/2)
To evaluate pharmacokinetic parameter of AC0010MA
Area under the plasma concentration-time curve
To evaluate pharmacokinetic parameter of AC0010MA
Volume of distribution (V/F)
To evaluate pharmacokinetic parameter of AC0010MA
Plasma Concentration (CL/F)
To evaluate pharmacokinetic parameter of AC0010MA

Full Information

First Posted
May 12, 2015
Last Updated
October 28, 2019
Sponsor
ACEA Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02448251
Brief Title
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Official Title
A Phase I, Multicenter, Open-Label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients With Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Study Start Date
May 2015 (Actual)
Primary Completion Date
October 2019 (Actual)
Study Completion Date
October 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ACEA Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
AC0010MA is a new, irreversible, Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor. Aim at local advanced or metastatic non-small cell lung cancer patients with EGFR mutation or T790M drug-resistant mutation. The molecular mechanism: by irreversible combining the EGFR-RTKs ATP binding site of cell, selectively suppress the activities of EGFR tyrosine kinase phosphorylation, block the signal transduction pathway of EGFR and inhibit the function of ras/raf/MAPK downstream, thus block the tumor cell growth by EGFR induction, and promotes apoptosis. AC0010MA Maleate Capsules has three characters: 1. Irreversible binding to EGFR; 2. Effectively suppresses the tumor cell with EGFR mutant while has no suppression to EGFR wild-type cell; 3. Efficient suppress the tumor cell with EGFR T790M drug-resistant mutation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
single dose per day (QD)
Arm Type
Experimental
Arm Description
Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
Arm Title
two doses per day (BID)
Arm Type
Experimental
Arm Description
Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
Intervention Type
Drug
Intervention Name(s)
AC0010MA
Intervention Description
Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
Primary Outcome Measure Information:
Title
Safety and tolerability, and the maximum tolerated dose (MTD) of AC0010MA determined by incidence of dose limiting toxicity (DLT)
Description
To determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of AC0010MA by incidence of dose limiting toxicity (DLT), defined as Grade 3 or 4 adverse events (AEs) and clinical lab abnormalities occurring within the first 28 days of treatment.
Time Frame
Within the first 28 days of treatment.
Secondary Outcome Measure Information:
Title
Evaluation of tumor response and duration of response of AC0010MA ((objective response rate, ORR)
Description
To characterize tumor response (objective response rate, ORR) and duration of response of AC0010MA as a criterion for further development of AC0010MA in this patient population.
Time Frame
within the time frame of every 8 weeks (2 cycles) for up to 3 years
Title
Maximum plasma concentration (Cmax) of AC0010MA
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I
Title
Time to Cmax
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I
Title
Terminal half-life (t1/2)
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I
Title
Area under the plasma concentration-time curve
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I
Title
Volume of distribution (V/F)
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I
Title
Plasma Concentration (CL/F)
Description
To evaluate pharmacokinetic parameter of AC0010MA
Time Frame
Blood samples will be collected at pre-treatment, and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-treatment on Days 1, 8, and 28 in the first treatment cycle (QD and BID) in Phase I

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is male or female, aged 18 years or older at the time of consent; preferably non-Asian. Has histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC. Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Has documented evidence of an activating EGFR mutation in the tumor tissue determined by either sequencing or PCR-based technique (Part 1). For Part 1 only: subjects with a positive T790M mutation are preferred, but not required. Confirmation of T790M mutation status will be determined from an archived tumor tissue sample or fresh tumor tissue sample obtained via biopsy if archived tissue is not available. In Part 2, subjects must have a confirmed, positive T790M EGFR mutation (acquired T790M EGFR mutation or "de novo" T790M EGFR mutation). Has a life expectancy of at least 3 months. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Has adequate hematological and physiological functions. Has documented disease progression while receiving at least 30 days of treatment with a currently approved EGFR tyrosine kinase inhibitor (TKI) (e.g., erlotinib, gefitinib or afatinib) with intervening treatment after most recent EGFR TKI therapy (not required for "de novo" T790M EGFR mutation). Signed and dated written informed consent obtained prior to any study-specific evaluation. Exclusion Criteria: Has a history of interstitial lung disease related to prior EGFR inhibitor therapy. Has an EGFR TKI- related toxicity that has NOT resolved to Grade 1 or less. Is test positive for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) antibody. Has received the prohibited therapy (e.g., concurrent anti-cancer therapy including but not limited to: chemotherapy, radiation, hormonal, or immunotherapy) ≤14 days prior to first planned dose of AC0010MA. Received prior treatment with AZD9291 (osimertinib) or CO1686 (rociletinib) and experienced disease progression. Is a female subject who is pregnant or breastfeeding. Female subjects (if of child bearing potential) and male subjects (with a partner of child bearing potential) must use medically acceptable methods of birth control before study entry, for the duration of the study, and for at least 6 months after the last intake of study drug. Has a serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled psychiatric condition, uncontrolled intercurrent illness including active infection, arterial thrombosis, or symptomatic pulmonary embolism). Has any other reason(s) for the investigator to consider that the subject should not participate in the study. Is receiving treatment with medication(s) that are known to be strong inhibitors or inducers of CYP3A4/5.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vali A. Papadimitrakopoulou, MD
Organizational Affiliation
MD Anderson Cancer Center, Houston, TX, USA
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Suresh S. Ramalingam, MD
Organizational Affiliation
Emory University School of Medicine, Atlanta, GA, USA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Heather Wakelee, MD
Organizational Affiliation
Stanford University, Palo Alto, CA, USA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karen L Reckamp, MD
Organizational Affiliation
City of Hope Comprehensive Cancer Center, Duarte, CA, USA
Official's Role
Principal Investigator
Facility Information:
Facility Name
City of Hope Comprehensive Cancer Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
Emory University School of Medicine
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
CEPCM - Hopital Timone
City
Marseille
ZIP/Postal Code
13005
Country
France
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
START-Madrid-FJD
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
START-Madrid-CIOCC
City
Madrid
ZIP/Postal Code
28050
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

We'll reach out to this number within 24 hrs